お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
973286

SB-913 - 新薬の考察と市場予測:2030年

SB-913- Emerging Drug Insight and Market Forecast - 2030

出版日: 受注後作成 | 発行: DelveInsight Business Research LLP | ページ情報: 英文 60 Pages | 納期: 約10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=107.06円
SB-913 - 新薬の考察と市場予測:2030年
出版日: 受注後作成
発行: DelveInsight Business Research LLP
ページ情報: 英文 60 Pages
納期: 約10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

SB-913は、Sangamoが開発中の、ムコ多糖症II型 (MPS II; Hunter症候群) を対象としたもので、ZFNを介したin vivoゲノム編集を用いて、IDS (イドロネート2-スルファターゼ) 遺伝子の正常な機能コピーを、患者の肝臓の強力なアルブミンプロモーターの制御下に配置します。

当レポートでは、主要7ヶ国 (米国、ドイツ、フランス、イタリア、スペイン、英国、日本) におけるSB-913について調査分析し、製品の詳細と将来の市場評価について、体系的な情報を提供しています。

目次

第1章 医薬品の概要

  • 製品の詳細
  • 作用機序
  • 用法・用量
  • 研究開発活動
    • 臨床開発
    • 安全性と有効性
  • その他の開発活動

第2章 市場評価

  • 主要7ヶ国市場分析
  • 米国市場
  • ドイツ市場
  • フランス市場
  • イタリア市場
  • スペイン市場
  • 英国市場
  • 日本市場

第3章 SWOT分析

第4章 アナリストの見解

第5章 市場の競合企業

第6章 その他の新薬

第7章 付録

第8章 レポート購入オプション

図表

List of Tables

  • Table 1 SB-913, Description
  • Table 2 SB-913, Clinical Trial Description
  • Table 3 SB-913, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Table 4 Market Competitors
  • Table 5 Other Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of SB-913
  • Figure 2 Patent Details, SB-913
  • Figure 3 SB-913, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Figure 4 SB-913, US Market Size from 2020 to 2030 (in Millions USD)
  • Figure 5 SB-913, EU5 Market Size from 2020 to 2030 (in Millions USD)
  • Figure 6 SB-913, Japan Market Size from 2020 to 2030 (in Millions USD)
目次
Product Code: DIDM0087

"SB-913- Emerging Drug Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Hunter Syndrome in 7 Major Markets. A detailed picture of the SB-913 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Drug Summary:

SB-913 is being developed by Sangamo in mucopolysaccharidosis type II (MPS II; Hunter syndrome), which uses ZFN-mediated in vivo genome editing to place a normal functioning copy of the IDS (iduronate 2-sulfatase) gene under the control of the strong albumin promoter in the patient's liver.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around SB-913.
  • The report contains forecasted sales for SB-913 till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) for Hunter Syndrome.
  • The report also features the SWOT analysis with analyst insights and key findings of SB-913.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SB-913 Analytical Perspective by DelveInsight

  • In-depth SB-913 Market Assessment

This report provides a detailed market assessment of SB-913 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

  • SB-913 Clinical Assessment

The report provides the clinical trials information of SB-913 covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for Hunter Syndrome is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence SB-913 dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Hunter Syndrome are giving market competition to SB-913 and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of SB-913.
  • Our in-depth analysis of the forecasted sales data of SB-913 from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the SB-913.

Key Questions:

  • Which company is developing SB-913 along with the phase of the clinical study?
  • What is the technology utilized in the development of SB-913?
  • What is the product type, route of administration and mechanism of action of SB-913?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SB-913 development?
  • What are the key designations that have been granted to SB-913?
  • What is the forecasted market scenario of SB-913?
  • What is the history of SB-913 and what is its future?
  • What is the forecasted sales of SB-913 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to SB-913?
  • Which are the late-stage emerging therapies under development for the treatment of the Hunter Syndrome?

Table of Contents

1. Drug Overview

  • 1.1. Product Detail
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
  • 1.4. Research and development activity
    • 1.4.1. Clinical Development
    • 1.4.2. Safety and Efficacy
  • 1.5. Other Development Activities

2. Market Assesment

  • 2.1. 7MM Market Analysis
  • 2.2. The United States Market
  • 2.3. Germany Market
  • 2.4. France Market
  • 2.5. Italy Market
  • 2.6. Spain Market
  • 2.7. United Kingdom Market
  • 2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.